Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colitis 1Burkitt Lymphoma 1

Interventions

Infliximab 4vedolizumab 3Fecal Microbiota Transplantation 3Prednisone 2LDP-02 2Immunoglobulin G 2Disulfides 2CT-P13 2prednylidene 1deltacortene 1Standard of Care 1Practice Guidelines as Topic 1Photopheresis 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Methoxsalen 1Loperamide 1Endoscopy 1Azathioprine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colitis × Methylprednisolone Hemisuccinate × 1 year × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡